Ethyl Acetate

Ethyl Acetate

SCHEMBL2385899

CCN(CC)CC.CCOC(C)=O.ClC(Cl)Cl

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
LMNA P02545 2/20 0.61
HSD17B10 Q99714 1/20 0.61
TSHR P16473 1/20 0.40
TRPA1 O75762 1/20 0.38
GAA P10253 2/20 0.36
ALOX15 P16050 1/20 0.36
MGAM O43451 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
SOAT1 P35610 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
GLO1 Q04760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL6338631 0.98 ALDH1A1 (0.58) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL28814573 0.96 ALDH1A1 (0.56) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL6064388 0.94 ALDH1A1 (0.58) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL6347449 0.91 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL276158 0.91 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL5861342 0.91 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL6046507 0.91 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL1231 0.89 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL11579143 0.89 ALDH1A1 (0.70) ALDH1A1LMNAHSD17B10TSHRTRPA1
Ethyl Acetate SCHEMBL3507062 0.89 ALDH1A1 (0.70) ALDH1A1LMNAHSD17B10TSHRTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117269403-B Thin-layer identification method of medicinal material Zanthoxylum bungeanum in Chinese medicinal composition containing Zanthoxylum bungeanum 湖南易能生物医药有限公司 2024-04-26 CN disclosed
CN-117269403-A Thin-layer identification method of medicinal material Zanthoxylum bungeanum in Chinese medicinal composition containing Zanthoxylum bungeanum 湖南易能生物医药有限公司 2023-12-22 CN disclosed
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed
EP-1212096-A2 DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME Brenner, Sydney (US) 2002-06-12 EP disclosed
WO-2001013958-A2 DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME BRENNER SYDNEY (US) 2001-03-01 WO disclosed
US-5476931-A Reacting with a base in a mixed solvent containing alcohol RIKAGAKU KENKYUSHO (JP) 1995-12-19 US disclosed
EP-0311694-B1 NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION RIKAGAKU KENKYUSHO (JP) 1995-12-13 EP disclosed
US-5380722-A Antiarrhythmia agents ROUSSEL-UCLAF (FR) 1995-01-10 US disclosed
US-5208234-A Hypotensive E. R. SQUIBB & SONS, INC. (US) 1993-05-04 US disclosed
US-5208235-A Phosphonic or phosphinic acid derivatives as inhibitors of angiotnesin II for cardiovascular disorders and hypotensives E. R. SQUIBB & SONS, INC. (US) 1993-05-04 US disclosed
US-5144018-A Antiviral Agents RIKAGAKU KENKYUSHO (JP) 1992-09-01 US disclosed
US-4908367-A Antiarrythmic agents Uclaf, Roussel (FR) 1990-03-13 US disclosed
EP-0311694-A1 NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION RIKAGAKU KENKYUSHO (JP) 1989-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 ALDH1A1 2376/4885LMNA 1834/4885HSD17B10 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.